Michael Mason's most recent trade in Karyopharm Therapeutics Inc was a trade of 7,050 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on Sept. 4, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 0.72 per share. | 04 Sep 2024 | 7,050 | 391,054 (0%) | 0% | 0.7 | 5,089 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 0.99 per share. | 04 Jun 2024 | 652 | 398,104 (0%) | 0% | 1.0 | 645 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 29 Feb 2024 | 27,687 | 404,918 (0%) | 0% | 1.2 | 32,394 | Common |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 1.20 per share. | 29 Feb 2024 | 6,162 | 398,756 (0%) | 0% | 1.2 | 7,394 | Common |
| Karyopharm Therapeutics Inc | Mason Michael | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 188,205 | 432,605 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Mason Michael | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 27 Feb 2024 | 2,545 | 244,400 (0%) | 0% | 1.3 | 3,369 | Common Stock |
| Karyopharm Therapeutics Inc | Mason Michael | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 1.59 per share. | 06 Feb 2024 | 4,205 | 246,945 (0%) | 0% | 1.6 | 6,671 | Common Stock |
| Karyopharm Therapeutics Inc | Mason Michael | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 13,333 | 251,150 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 2.22 per share. | 02 Jun 2023 | 631 | 244,730 (0%) | 0% | 2.2 | 1,401 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 95,000 | 256,566 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.03 per share. | 28 Feb 2023 | 11,205 | 245,361 (0%) | 0% | 3.0 | 33,942 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.04 per share. | 27 Feb 2023 | 2,802 | 161,566 (0%) | 0% | 3.0 | 8,509 | Common Stock |
| Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 345.12 per share. | 10 Feb 2023 | 8,023 | 39,284 (0%) | 0% | 345.1 | 2,768,898 | Common Stock |
| Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 3,490 | 3,490 | - | - | Restricted Stock Unit | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.40 per share. | 06 Feb 2023 | 4,141 | 164,368 (0%) | 0% | 3.4 | 14,079 | Common Stock |
| Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 6,690 | 34,196 (0%) | 0% | 0 | Common Stock | |
| Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 6,690 | 0 | - | - | Restricted Stock Unit | |
| Eli Lilly | Michael B. Mason | EVP & Pres., Lilly Diabetes | Payment of exercise price or tax liability using portion of securities received from the company at price $ 344.15 per share. | 01 Feb 2023 | 2,935 | 31,261 (0%) | 0% | 344.1 | 1,010,080 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 30,000 | 168,509 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO, Treasurer | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 03 Jun 2022 | 598 | 138,512 (0%) | 0% | 6.0 | 3,612 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO, Treasurer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 03 Jun 2022 | 3 | 138,509 (0%) | 0% | 6 | 18 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 111,600 | 111,600 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 88,200 | 141,508 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 2,398 | 139,110 (0%) | 0% | 10.2 | 24,550 | Common Stock |
| Eli Lilly | Michael B. Mason | Sr. VP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 6,690 | 6,690 | - | - | Restricted Stock Unit | |
| Eli Lilly | Michael B. Mason | Sr. VP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 243.27 per share. | 09 Feb 2022 | 2,612 | 27,506 (0%) | 0% | 243.3 | 635,421 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 3,947 | 53,308 (0%) | 0% | 9.9 | 38,925 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Mason | EVP, CFO, Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 5,500 | 57,255 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Mason | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 59,968 | 59,968 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Mason | SVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 22,013 | 51,755 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Mason | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 15.52 per share. | 11 Feb 2021 | 2,858 | 5,292 (0%) | 0% | 15.5 | 44,354 | Common Stock |
| Eli Lilly | Michael B. Mason | Sr. VP & Pres., Lilly Diabetes | Grant, award, or other acquisition of securities at price $ 205.77 per share. | 08 Feb 2021 | 6,350 | 24,894 (0%) | 0% | 205.8 | 1,306,640 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Mason | SVP, CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 8,150 | 24,450 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Michael Mason | SVP, CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 8,150 | 8,150 (0%) | 0% | - | Common Stock |